Summarising the use of thiazolidinediones with insulin

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 2, 2007, Pages 75-80

  Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Combination therapy; Insulin; Pioglitazone; Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLITAZONE DERIVATIVE; INSULIN; INSULIN ASPART; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARM FRACTURE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC ANGIOPATHY; DIABETOGENESIS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FOOT FRACTURE; FRACTURE; GLYCEMIC CONTROL; HAND FRACTURE; HUMAN; HUMERUS FRACTURE; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT MONITORING; PLASMA VOLUME; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SODIUM RETENTION; WEIGHT GAIN;

EID: 34249066430     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070020501     Document Type: Article

References (47)

1. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
4. Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4(suppl 6):S11-S18.
5. Smiley T, Oh P, Shane LG. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes - a systematic review. Can J Cardiol 2001; 17:797-805.
6. Bonora E, Calcaterra F, Lombardi S et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-9.
7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49:1711-21.
8. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000;106:1305-07.
9. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
10. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226-32.
11. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11.
12. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409.
13. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.
14. Rosenstock J, Goldstein B, Vinik AI et al. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (> 60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8:49-57.
15. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34.
16. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166-74.
17. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:175-85.
18. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23.
19. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-68.
20. Tran MT, Navar MD, Davidson MB. Comparison of the glycemic effects of rosiglitzone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care 2006;29:1395-6.
21. Charbonnel B, Scheen A. Pioglitazone in triple oral therapy: long-term glycemic results from PROactive. Diabetes 2006;55(suppl 1):A135.
22. Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive. Diabetes 2006;55(suppl 1):A134.
23. Rosenstock J, Rood J, Cobitz A, Huang C, Garber A. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 2006;8:643-9.
24. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006; 66:1863-77.
25. Actos® (pioglitazone) licence change gives new treatment option to patients with type 2 diabetes. Takeda UK Ltd press release, 9 Nov 2006. Available from: http://dave.md/s/PressReleases/Takeda110906.pdf.
26. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005;5:201-09.
27. Bell DSH. Dyslipidemia in type 2 diabetes and the effects of thiazolidinediones. Endocrinologist 2003;13:496-504.
28. Haffner S, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679-84.
29. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.
30. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45:1925-31.
31. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
32. Schmitz O. Influence of rosiglitazone treatment on A-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. I Clin Endocrinol Metab 2003;88:3794-800.
33. Xiang A, Peters R, Kjos S et al. Effect of pioglitazone on pancreatic A-cell function and diabetes risk in hispanic women with gestational diabetes. Diabetes 2006;55:517-22.
34. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
35. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
36. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226-32.
37. Garg R, Gopal J, Jones GR. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone. J Diabetes Complications 2007;21:1-6.
38. Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Harman-Boehm I. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109-23.
39. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7.
40. Davidson JA, Perez A, Zhang J, the Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006; 8:164-74.
41. Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27:554-67.
42. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62:1463-80.
43. Huang A, Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 2005;4:205-20.
44. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
45. Takeda UK Ltd. Actos tablets. Summary of Product Characteristics, 2007.
46. GlaxoSmithKline UK. Avandia 4 mg and 8 mg tablets. Summary of Product Characteristics, 2006.
47. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18(suppl 2):S23-S29.